Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Bristol Myers Squibb (NYSE:BMY) primarily generates revenue by developing and selling prescription medicines for oncology, immunology, and cardiovascular diseases. It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas. Pfizer (NYSE:PFE) primarily generates revenue by manufacturing and distributing a broad portfolio of prescription medicines and vaccines worldwide.

CryptoAlerta — análise de criptomoedas e mercado em tempo real